Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan

Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagi, Yoshitaka, Kim, Young Hak, Tajima, Noriyuki, Baba, Kiichiro, Aihara, Kensaku, Soo, Hong Hyun, Yamaoka, Shinpachi, Mishima, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861861/
https://www.ncbi.nlm.nih.gov/pubmed/24348395
http://dx.doi.org/10.1159/000356826
_version_ 1782295692096569344
author Yagi, Yoshitaka
Kim, Young Hak
Tajima, Noriyuki
Baba, Kiichiro
Aihara, Kensaku
Soo, Hong Hyun
Yamaoka, Shinpachi
Mishima, Michiaki
author_facet Yagi, Yoshitaka
Kim, Young Hak
Tajima, Noriyuki
Baba, Kiichiro
Aihara, Kensaku
Soo, Hong Hyun
Yamaoka, Shinpachi
Mishima, Michiaki
author_sort Yagi, Yoshitaka
collection PubMed
description Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the majority of patients develop recurrence and the prognosis of such patients is reportedly 2–4 months. Evolution of the treatment for SCLC has stagnated, and cisplatin + etoposide has been the standard chemotherapy for decades. Meanwhile, the combination of cisplatin + irinotecan has demonstrated equivalent efficacy to cisplatin + etoposide. Recently, maintenance chemotherapy has been extensively investigated in non-small-cell lung cancer (NSCLC), and is currently recommended as a standard treatment in clinical guidelines. On the contrary, a maintenance strategy has not been established for SCLC. Here, we describe an SCLC patient who received maintenance chemotherapy with irinotecan for more than 2 years after induction chemotherapy with cisplatin + irinotecan, and survived long term with no recurrence.
format Online
Article
Text
id pubmed-3861861
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-38618612013-12-13 Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan Yagi, Yoshitaka Kim, Young Hak Tajima, Noriyuki Baba, Kiichiro Aihara, Kensaku Soo, Hong Hyun Yamaoka, Shinpachi Mishima, Michiaki Case Rep Oncol Published online: November, 2013 Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the majority of patients develop recurrence and the prognosis of such patients is reportedly 2–4 months. Evolution of the treatment for SCLC has stagnated, and cisplatin + etoposide has been the standard chemotherapy for decades. Meanwhile, the combination of cisplatin + irinotecan has demonstrated equivalent efficacy to cisplatin + etoposide. Recently, maintenance chemotherapy has been extensively investigated in non-small-cell lung cancer (NSCLC), and is currently recommended as a standard treatment in clinical guidelines. On the contrary, a maintenance strategy has not been established for SCLC. Here, we describe an SCLC patient who received maintenance chemotherapy with irinotecan for more than 2 years after induction chemotherapy with cisplatin + irinotecan, and survived long term with no recurrence. S. Karger AG 2013-11-14 /pmc/articles/PMC3861861/ /pubmed/24348395 http://dx.doi.org/10.1159/000356826 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: November, 2013
Yagi, Yoshitaka
Kim, Young Hak
Tajima, Noriyuki
Baba, Kiichiro
Aihara, Kensaku
Soo, Hong Hyun
Yamaoka, Shinpachi
Mishima, Michiaki
Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title_full Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title_fullStr Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title_full_unstemmed Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title_short Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
title_sort long survival of a small-cell lung cancer patient who received maintenance chemotherapy with irinotecan
topic Published online: November, 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861861/
https://www.ncbi.nlm.nih.gov/pubmed/24348395
http://dx.doi.org/10.1159/000356826
work_keys_str_mv AT yagiyoshitaka longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT kimyounghak longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT tajimanoriyuki longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT babakiichiro longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT aiharakensaku longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT soohonghyun longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT yamaokashinpachi longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan
AT mishimamichiaki longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan